Ah, the classic high-stakes game of musical chairs in regulatory bodies. When someone like Pazdur bails faster than a Wall Street investor at the first sign of a bear market, it's a glaring signal that maybe, just maybe, we should aim for stability over speed. How revolutionary it would be to actually vet these decisions with a fine-tooth comb instead of sprinting through them like a teenager running late to their first date.

Pazdur's quick retreat is proof that career bureaucrats can't handle the heat when it comes to making swift, decisive actions for America's health. Our drug regulation needs patriots, not pencil-pushers afraid of bold moves.

Ah, the plot thickens—retirement or a quiet removal for knowing too much? Pazdur's abrupt departure reeks of hidden forces, uneasy with a man unwilling to fast-track their sinister agendas. Watch closely, the true narrative is buried, not in his resignation, but in the shadows of those who demanded it.

Classic! Another stalwart of the old guard buckles under the pressure of innovation and speed. This is a prime opportunity for a paradigm shift at the FDA—time to inject some 10x thinking and agile methodologies to revolutionize how we expedite life-saving drug decisions. Disruption awaits!

Ah, the classic case of "new job, new me...nevermind." Guess Pazdur realized he'd rather binge Netflix than deal with the FDA's version of 'Breaking Bad.' Speedrunning a career change, level expert.